Actelion & Nippon Shinyaku vs. Cipla: Selexipag Patent Victory Secured by Consent Judgment
Que souhaitez-vous faire ensuite ?
Choisissez votre parcours en fonction de vos besoins actuels :
📋 Résumé de l'affaire
| Nom de l'affaire | Actelion Pharmaceuticals US, Inc. et al. v. Cipla Limited et al. |
| Numéro de dossier | 1:22-cv-01450 (D. Del.) |
| Tribunal | Tribunal fédéral de première instance pour le district du Delaware |
| Durée | Nov 2022 – Aug 2024 1 year 9 months |
| Résultat | Plaintiff Win — Permanent Injunction |
| Brevets en cause | |
| Produits incriminés | Selexipag for injection 1.8 mg/vial (generic Uptravi® IV) |
Aperçu du dossier
Les parties
⚖️ Demandeur
Subsidiaries of Johnson & Johnson’s Janssen division and Nippon Shinyaku Co., Ltd., holding IP for Uptravi®, an FDA-approved therapy for pulmonary arterial hypertension (PAH).
🛡️ Défendeur
Prominent generics manufacturers with an extensive ANDA pipeline, specializing in various therapeutic areas including pulmonary arterial hypertension.
Les brevets en cause
This case centered on two foundational selexipag patents protecting specific polymorphic crystal form claims — a sophisticated and commercially critical layer of pharmaceutical IP strategy. Such patents are frequently challenged on grounds of obviousness (§103) or lack of written description (§112).
- • U.S. Patent No. 8,791,122 — Covers the Form-I crystal of selexipag and methods for its production.
- • U.S. Patent No. 9,284,280 — Covers the use of the same Form-I crystalline compound, extending IP protection.
Développer un médicament générique ?
Ensure your ANDA product doesn’t infringe existing crystalline form or method-of-use patents.
Le verdict et l'analyse juridique
Résultat
The case resolved via Consent Judgment and Order of Permanent Injunction. Cipla Limited and Cipla USA, Inc. acknowledged the validity and enforceability of U.S. Patent Nos. 8,791,122 and 9,284,280 and agreed to a permanent injunction, blocking their generic selexipag injection product until patent expiration. No monetary damages were publicly disclosed.
Analyse des causes du verdict
The action was a classic Hatch-Waxman paragraph IV ANDA infringement suit, triggered by Cipla’s ANDA No. 216607. The crystalline form patents, protecting the Form-I polymorph of selexipag, represent a sophisticated layer of pharmaceutical patent protection. Cipla’s stipulation to validity indicates a strategic decision to resolve the litigation rather than risk adverse rulings at trial.
Signification juridique
The explicit acknowledgment of patent validity and enforceability in the consent judgment, though limited to this action, sets a precedent. It strengthens Actelion and Nippon Shinyaku’s position against other ANDA filers for Uptravi® IV, including remaining defendants Alembic and Lupin. This outcome reinforces that crystalline form patents are powerful tools in pharmaceutical lifecycle management strategies.
Points stratégiques à retenir
For Patent Holders: Layering composition-of-matter patents with use and method claims creates multi-dimensional enforcement leverage. Seeking permanent injunctions via consent judgment preserves IP protection without the precedential risk of adverse claim construction rulings at trial.
For Accused Infringers (ANDA Filers): A thorough evaluation of invalidity defenses, especially against polymorphic form claims, is critical before committing to Paragraph IV certification litigation. Consent judgments with dismissal without prejudice can preserve future optionality if the patent landscape changes.
For R&D and Regulatory Teams: Design-around strategies for crystalline form patents are scientifically and commercially demanding. Freedom-to-operate (FTO) analyses must meticulously account for base compound patents, and downstream form, use, and manufacturing process patents.
Analyse de la liberté d'exploitation (FTO)
Ce cas met en évidence les risques critiques liés à la propriété intellectuelle dans le développement de produits pharmaceutiques. Choisissez la prochaine étape :
📋 Comprendre l'impact de cette affaire
Découvrez les risques et les implications spécifiques liés à ce litige pharmaceutique.
- Voir tous les brevets liés à ce domaine thérapeutique
- See which companies are most active in PAH drug patents
- Understand crystalline form patent trends
🔍 Vérifier les risques liés à mon produit
Réalisez une analyse FTO complète pour votre propre composé pharmaceutique ou votre propre formulation.
- Input your compound structure or technical features
- AI identifies potentially blocking polymorphic patents
- Obtenir un rapport d'évaluation des risques exploitable
Zone à haut risque
Crystalline form patents for API
2 brevets à l'honneur
US8791122 & US9284280
Options de contournement
Complex, but feasible with specific polymorphs
✅ Points clés à retenir
Consent judgments with validity stipulations are powerful enforcement outcomes in ANDA litigation, avoiding trial exposure.
Rechercher la jurisprudence connexe →Crystalline form patents continue to withstand challenge when properly prosecuted with robust written description and non-obviousness support.
Explorer les précédents →Delaware remains the premier jurisdiction for pharmaceutical patent enforcement due to its experienced bench and predictable procedures.
Analyser les tendances judiciaires →Foire aux questions
The case involved U.S. Patent Nos. 8,791,122 and 9,284,280, both covering the Form-I crystalline structure of selexipag and its applications, protecting the active ingredient in Uptravi® IV.
Cipla stipulated to the validity and enforceability of both patents and agreed to a permanent injunction barring commercialization of its ANDA product (selexipag for injection 1.8 mg/vial) until patent expiration, resolving the action without a full merits trial.
The validity stipulation and permanent injunction strengthen Actelion and Nippon Shinyaku’s enforcement posture against remaining ANDA filers, signaling robust patent coverage that generic challengers must overcome through alternative legal strategies or post-grant proceedings.
Prêt à renforcer votre stratégie en matière de brevets ?
Rejoignez plus de 18 000 professionnels de la propriété intellectuelle qui utilisent PatSnap Eureka pour effectuer des recherches d'antériorité, rédiger des brevets et analyser le paysage concurrentiel avec une précision optimisée par l'IA.
Références
- PACER Case Lookup – 1:22-cv-01450
- USPTO Patent Full-Text Database – US 8,791,122
- USPTO Patent Full-Text Database – US 9,284,280
- FDA Orange Book – Hatch-Waxman Litigation Guide
- PatSnap — Solutions de veille en matière de propriété intellectuelle pour les cabinets d'avocats
Cet article est publié à titre purement informatif et ne constitue en aucun cas un avis juridique. Toutes les informations relatives aux affaires sont tirées de dossiers judiciaires accessibles au public. Pour en savoir plus sur les fonctionnalités de la plateforme, rendez-vous sur PatSnap.